Adenosine

Mechanism-of-action classes: Adenosine Receptor Agonists; Structural Macromolecules.

• Uses Uses: Decrease the appearance of fine lines, wrinkles, scarring and discolorations of the skin

Directions Directions: 1. Wash the face and pat dry skin. Do not use toner before applying this product. 2. Apply 1/3 up to 2/2 of a dropper of the essence to face and neck, massaging in gently and evenly. 3. Allow the essence to dry. 4. The product may precipitate during long-term storage. However, it will not cause any quality problems. Make sure to shake well before using. 5. Reapplication to rapidly aging spots such as around the eyes and mouth is recommended. 6. After 1-2 minutes, when you feel some tension in your skin, apply moisturizer as usual. 7. For best results, apply twice a day, morning and night. 8. Single treatments are recommended at nighttime. 9. Store in a refrigerator (2-15℃) after each use.

Warnings: 1. For external use only. 2. Do not use on wounds and/or any inflammation of the skin. 3. Stop use and ask a doctor if you are experiencing any of the following symptoms: reddening or spotting of the skin, irritation, and/or increased sensitivity. 4. When using this product avoid contact with eyes. If irritation occurs, immediately cleanse with fresh water. 5. Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

• Apr 27, 2005ANDAANDA077133Fresenius Kabi Usa
• Jun 14, 2007ANDAANDA077283Gland Pharma Ltd
• May 13, 2009ANDAANDA078686Mylan Labs Ltd
• Aug 29, 2013ANDAANDA077425Meitheal
• Mar 28, 2014ANDAANDA090212Mylan Asi
• Sep 15, 2014ANDAANDA202313Avet Lifesciences
• Nov 2, 2017ANDAANDA205331Eugia Pharma
• Nov 27, 2017ANDAANDA077897Fresenius Kabi Usa

1. 1Drug Ineffective33521%
2. 2Off Label Use1046.5%
3. 3Supraventricular Tachycardia976.1%
4. 4Hypotension885.5%
5. 5Cardiac Arrest784.9%
6. 6Dyspnoea744.6%
7. 7Pain694.3%
8. 8Atrial Fibrillation674.2%
9. 9Bradycardia633.9%
10. 10Tachycardia613.8%
11. 11Anxiety553.4%
12. 12Nausea543.4%
13. 13Drug Interaction533.3%
14. 14Product Use In Unapproved Indication513.2%
15. 15Ventricular Tachycardia493.1%

Recent PubMed references pinned to Adenosine as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Computational evaluation of leflunomide and ticagrelor combination targeting the A2A receptor for the management of rheumatoid arthritis.
  Pakistan journal of pharmaceutical sciences · 2026 · Qayyum Khan M, Zaman M, Siddique W, et al.
  PMID 42262197DOI 10.36721/PJPS.2026.39.8.223.1
• FTO-mediated m(6)A demethylation of BCL6 promotes gastric cancer progression by suppressing ferroptosis.
  RNA biology · 2026 · Wang Y, Fan F, Zhan Z, et al.
  PMID 42262009DOI 10.1080/15476286.2026.2684406
• Stress native mapping does not distinguish patients with previous myocardial infarction with non-obstructive coronary arteries from healthy volunteers.
  Clinical physiology and functional imaging · 2026 · Andersson DF, Johansson RS, Tornvall P, et al.
  PMID 42244381DOI 10.1111/cpf.70070
• ABCD-GENE Score and Bleeding in Post-PCI Patients: Implications for Guided De-Escalation of Antiplatelet Therapy.
  Journal of cardiovascular pharmacology and therapeutics · 2026 · Coons JC, Polkowski K, Prebehalla L, et al.
  PMID 42227816DOI 10.1177/10742484261457268
• Homocysteine and S-adenosyl-L-homocysteine impair development and methylation in yeast and flies.
  Disease models & mechanisms · 2026 · Brunner MS, Habisch H, Hafner J, et al.
  PMID 42220211DOI 10.1242/dmm.052802
• Mutagenic Survey of Key Residues of NifB Involved in Radical SAM-Dependent Nitrogenase Cofactor Assembly.
  Chembiochem : a European journal of chemical biology · 2026 · Duffin C, Quechol R, Yang Y, et al.
  PMID 42218797DOI 10.1002/cbic.70400
• Single-base resolution atlas reveals moderate conservation and regulatory diversity of m6A modifications across mammals.
  Nucleic acids research · 2026 · Zhang X, Zhang Z, Liu W, et al.
  PMID 42216759DOI 10.1093/nar/gkag544
• Regulatory mechanisms and therapeutic potential of N6-methyladenosine modification in retinal diseases (Review).
  Molecular medicine reports · 2026 · Zhang W, Chen J, Zhong J, et al.
  PMID 42212360DOI 10.3892/mmr.2026.13923

The 10 most recently updated of 1,318 ClinicalTrials.gov registrations naming Adenosine as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
  Recruiting · Phase 1 · Phase 2 · Interventional · 80 enrolled · M.D. Anderson Cancer Center
  NCT04047641updated 2026-06-12
• Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
  Active not recruiting · Phase 3 · Interventional · 1,683 enrolled · University of Florida
  NCT05047172updated 2026-06-11
• Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
  Recruiting · Phase 2 · Interventional · 150 enrolled · M.D. Anderson Cancer Center
  NCT00412594updated 2026-06-11
• A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
  Terminated · Phase 2 · Interventional · 77 enrolled · Regeneron Pharmaceuticals
  NCT04916002updated 2026-06-09
• Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System
  Recruiting · Interventional · 2,950 enrolled · National Heart, Lung, and Blood Institute (NHLBI)
  NCT03331380updated 2026-06-08
• Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
  Recruiting · Phase 2 · Interventional · 145 enrolled · M.D. Anderson Cancer Center
  NCT03586609updated 2026-06-08
• A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
  Active not recruiting · Phase 2 · Interventional · 176 enrolled · Hoffmann-La Roche
  NCT04931342updated 2026-06-08
• Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease
  Recruiting · Observational · 800 enrolled · National Heart, Lung, and Blood Institute (NHLBI)
  NCT03685721updated 2026-06-08
• Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia
  Completed · Phase 1 · Phase 2 · Interventional · 37 enrolled · M.D. Anderson Cancer Center
  NCT04848974updated 2026-06-05
• A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
  Recruiting · Phase 2 · Interventional · 60 enrolled · M.D. Anderson Cancer Center
  NCT05365035updated 2026-06-05

Frequently asked questions

How does Adenosine work?

Mechanism-of-action classes: Adenosine Receptor Agonists; Structural Macromolecules.

What is Adenosine used for?

According to FDA labeling, Adenosine carries indications including: Uses Uses: Decrease the appearance of fine lines, wrinkles, scarring and discolorations of the skin. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.

What class of drug is Adenosine?

Adenosine is classified as Other cardiac preparations, Adenosine Receptor Agonist, Adenosine Receptor Agonists, Structural Macromolecules, Bronchoconstriction, Nodal Repolarization.

What are the brand names for Adenosine?

Adenosine is marketed under brand names including Adenocard, Adenoscan.